Novartis Pushes Up Nilotinib Filing Plans To Late 2006

The firm will position the tyrosine kinase inhibitor as a treatment for Gleevec-resistant or –intolerant patients.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet